Page 3 - பத்திரங்கள் மோசடி நடவடிக்கை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

HAGENS BERMAN Alerts Danimer Scientific (DNMR) Investors to Securities Fraud Action, Encourages Investors with Losses to Contact the Firm

SAN FRANCISCO, May 22, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Danimer Scientific, Inc. (NYSE:DNMR) investors with significant losses to submit your .

United statesHagens bermanReed kathreinDanimer scientific incKentucky department of environmental protectionDanimer scientificPlaintiff deadlineSecurities fraud actionWall street journalSpruce point capital managementEnvironmental protectionSpruce pointஒன்றுபட்டது மாநிலங்களில்கென்ஸ் பெர்மன்கெந்‌டகீ துறை ஆஃப் சுற்றுச்சூழல் ப்ரொடெக்ஶந்பத்திரங்கள் மோசடி நடவடிக்கை

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Danimer Scientific (DNMR) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel

Danimer Scientific, Inc. (NYSE: DNMR) Securities Fraud Action: The complaint alleges that Danimer made misrepresentations and omissions concerning its production of polyhydroxyalkanoate ( PHA ) – a biodegradeable alternative to petrochemical-based plastics, which the company sells under its proprietary Nodax brand for usage in water bottles, straws, and food containers. The truth emerged over a series of disclosures, beginning on Mar. 20, 2021, when the Wall Street Journal questioned whether Nodax s breaks down far more quickly than fossil-fuel plastics, finding many claims about Nodax s are exaggerated and misleading. One plastics expert labeled Danimer s claims about Nodax s biodegradability as not accurate and as greenwashing. Next, on Apr. 22, 2021 analyst

United statesHagens bermanReed kathreinHagens berman sobol shapiroDanimer scientific incKentucky department of environmental protectionDanimer scientificPlaintiff deadlineSecurities fraud actionWall street journalSpruce point capital managementEnvironmental protectionSpruce pointBerman sobol shapiroHagens berman sobol shapiro llpஒன்றுபட்டது மாநிலங்களில்

PCT INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud

PCT INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

Hagens bermanReed kathreinPurecycle technologies incHindenburg researchPurecycle technologiesPlaintiff deadlineCycle technologiesSecurities fraud actionLatest zero revenueகென்ஸ் பெர்மன்ஹிண்டன்பர்க் ஆராய்ச்சிமிதிவண்டி தொழில்நுட்பங்கள்பத்திரங்கள் மோசடி நடவடிக்கை

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages PureCycle Technologies (PCT) Investors to Contact Firm s Attorneys Now, Securities Fraud Case Filed

/PRNewswire/ Hagens Berman urges PureCycle Technologies, Inc. (NASDAQ: PCT) investors with significant losses to submit your losses now. A class action has.

Hagens bermanReed kathreinPurecycle technologies incHagens berman sobol shapiroHindenburg researchPurecycle technologiesPlaintiff deadlineCycle technologiesSecurities fraud actionLatest zero revenueBerman sobol shapiroHagens berman sobol shapiro llpகென்ஸ் பெர்மன்கென்ஸ் பெர்மன் சோபோல் ஷாபிரோஹிண்டன்பர்க் ஆராய்ச்சிமிதிவண்டி தொழில்நுட்பங்கள்

HAGENS BERMAN Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel

FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen s presentation of false data of roxadustat to make the anemia drug look safer than it is. Throughout the Class Period, FibroGen touted the prospects of roxadustat. A key selling point for the drug was its purported heart safety as compared to standard of care erythropoietin (EPO) injectable therapies, which cannot be proscribed to a variety of patients at risk of major cardiac events. To support this marketing edge, FibroGen presented data from phase 3 trials purportedly showing roxadustat was safer than EPO, among other at risk populations, in incident dialysis patients.

Enrique conternoHagens bermanReed kathreinFibrogen incHagens berman sobol shapiroPlaintiff deadlineSecurities fraud actionClass periodBerman sobol shapiroகென்ஸ் பெர்மன்கென்ஸ் பெர்மன் சோபோல் ஷாபிரோபத்திரங்கள் மோசடி நடவடிக்கைவர்க்கம் காலம்பெர்மன் சோபோல் ஷாபிரோ